{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T10:46:21Z","timestamp":1772102781510,"version":"3.50.1"},"reference-count":78,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Theranostics, the practice of using a diagnostic radiopharmaceutical to guide radiotherapy with a chemically identical (or nearly identical) therapeutic radiopharmaceutical, is an exciting new field under development within the auspices of nuclear medicine. We aim to provide a narrative review of the areas of theranostics use and development which are occurring specifically in the head and neck, with attention to the therapeutic use of existing diagnostically used radiotracers such as agents that target prostate-specific membrane antigen (PSMA) and somatostatin receptors (e.g., DOTATATE derivatives), as well as developing classes of radiotracers such as those targeting fibrinogen-activating protein (FAP) and carbonic anhydrase IX (CAIX), as well as new meta-iodo-benzylguanidine (MIBG) derivatives. Most of those agents are still at the preclinical or early clinical stages of development, but as this is an emerging field, we aim to both outline current progress and suggest future directions.<\/jats:p>","DOI":"10.3390\/cancers17040695","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T03:29:53Z","timestamp":1739935793000},"page":"695","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Look to the Future: Potential Theranostic Applications in Head and Neck Tumors"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8979-2010","authenticated-orcid":false,"given":"Jorge D.","family":"Oldan","sequence":"first","affiliation":[{"name":"Molecular Imaging and Therapeutics, Department of Radiology, University of North Carolina, Chapel Hill, NC 27599, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilja B.","family":"Solnes","sequence":"additional","affiliation":[{"name":"The Russell H. Morgan Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bennett B.","family":"Chin","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Colorado Anschutz Medical Campus, Boulder, CO 80045, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[{"name":"Molecular Imaging and Therapeutics, Department of Radiology, University of North Carolina, Chapel Hill, NC 27599, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"ref_1","first-page":"299","article-title":"Theragnostics before we found its name","volume":"65","author":"Modoni","year":"2021","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.diii.2024.04.004","article-title":"The cutting edge: Promising oncology radiotracers in clinical development","volume":"105","author":"Oldan","year":"2024","journal-title":"Diagn. Interv. Imaging"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13550-022-00922-x","article-title":"A pilot study of (68) Ga-PSMA-617 PET\/CT imaging and (177)Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma","volume":"12","author":"Wang","year":"2022","journal-title":"EJNMMI Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13550-021-00866-8","article-title":"First experiences with (177)Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer","volume":"11","author":"Willems","year":"2021","journal-title":"EJNMMI Res."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Terroir, M., Lamesa, C., Krim, M., Vija, L., Texier, J.S., Cassou-Mounat, T., Delord, J.P., Vallot, D., and Courbon, F. (2023). RadioLigand Therapy with [(177)Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France. Pharmaceuticals, 16.","DOI":"10.3390\/ph16050754"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/RLU.0000000000002645","article-title":"Radionuclide Therapy with 177Lu-PSMA in a Case of Metastatic Adenoid Cystic Carcinoma of the Parotid","volume":"44","author":"Kuyumcu","year":"2019","journal-title":"Clin. Nucl. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2967\/jnumed.122.264342","article-title":"PSMA-Directed Imaging and Therapy of Salivary Gland Tumors: A Single-Center Retrospective Study","volume":"64","author":"Civan","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1200\/JCO.2023.41.16_suppl.6099","article-title":"177Lu-PSMA radioligand therapy for patients with recurrent\/metastatic (R\/M) salivary gland cancer (SGC): A phase II pilot study","volume":"41","author":"Uijen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13550-020-0610-x","article-title":"(68)Ga-PSMA PET\/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with (177)Lu-PSMA-617","volume":"10","author":"Lodewijk","year":"2020","journal-title":"EJNMMI Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4103\/wjnm.WJNM_112_18","article-title":"(177)Lu-DOTATATE and (177)Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment","volume":"18","author":"Assadi","year":"2019","journal-title":"World J. Nucl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s12020-024-03707-5","article-title":"Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): Results from a single institutional retrospective analysis","volume":"84","author":"Rubino","year":"2024","journal-title":"Endocrine"},{"key":"ref_12","first-page":"155","article-title":"Peptide receptor radionuclide therapy in head and neck paragangliomas\u2014Report of 14 cases","volume":"136","author":"Estevao","year":"2015","journal-title":"Rev. Laryngol. Otol. Rhinol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00259-015-3029-2","article-title":"Peptide receptor radionuclide therapy with (90)Y\/ (177)Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours)","volume":"42","author":"Puranik","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1016\/j.wneu.2020.07.165","article-title":"Somatostatin Receptor-Targeted Radioligand Therapy in Head and Neck Paraganglioma","volume":"143","author":"Roll","year":"2020","journal-title":"World Neurosurg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1055\/s-0032-1311637","article-title":"Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL)","volume":"44","author":"Zovato","year":"2012","journal-title":"Horm. Metab. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1097\/RLU.0000000000004929","article-title":"Complete Response to 177 Lu-DOTATATE PRRT in a 9-Year-Old Child with Metastatic Carotid Body Paraganglioma","volume":"49","author":"Yadav","year":"2024","journal-title":"Clin. Nucl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.5582\/irdr.2021.01047","article-title":"Familial SDHB gene mutation in disseminated non-hypoxia-related malignant paraganglioma treated with [(90)Y]Y\/[(177)Lu]Lu-DOTATATE","volume":"10","author":"Lon","year":"2021","journal-title":"Intractable Rare Dis. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.mayocpiqo.2020.09.015","article-title":"Efficacy of (177)Lu-Dotatate Therapy in the Treatment of Recurrent Meningioma","volume":"5","author":"Zahid","year":"2021","journal-title":"Mayo Clin. Proc. Innov. Qual. Outcomes"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e692","DOI":"10.1097\/RLU.0000000000004307","article-title":"Management of a Patient with Metastatic Gastrointestinal Neuroendocrine Tumor and Meningioma Submitted to Peptide Receptor Radionuclide Therapy with 177 Lu-DOTATATE","volume":"47","author":"Pirisino","year":"2022","journal-title":"Clin. Nucl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"20584601221109919","DOI":"10.1177\/20584601221109891","article-title":"A rare case of metastatic atypical meningioma that highlights the shortcomings of treatment options at present","volume":"11","author":"Wrange","year":"2022","journal-title":"Acta Radiol. Open"},{"key":"ref_21","first-page":"1538","article-title":"Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: Benefit linked to 68Ga-DOTATATE\/-TOC uptake","volume":"18","author":"Seystahl","year":"2016","journal-title":"Neuro Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1055\/a-1200-0989","article-title":"Response assessment of somatostatin receptor targeted radioligand therapies for progressive intracranial meningioma","volume":"59","author":"Muther","year":"2020","journal-title":"Nuklearmedizin"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1078-0432.CCR-23-2533","article-title":"Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma","volume":"30","author":"Kurz","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.2967\/jnumed.123.266956","article-title":"Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up","volume":"65","author":"Severi","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s00270-019-02262-1","article-title":"Will (177)Lu-DOTATATE Treatment Become More Effective in Salvage Meningioma Patients, When Boosting Somatostatin Receptor Saturation? A Promising Case on Intra-arterial Administration","volume":"42","author":"Braat","year":"2019","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4103\/NI.Neurol-India-D-23-00252","article-title":"PRRT with Lu-177 DOTATATE in Treatment-Refractory Progressive Meningioma: Initial Experience from a Tertiary-Care Neuro-Oncology Center","volume":"72","author":"Puranik","year":"2024","journal-title":"Neurol. India"},{"key":"ref_27","first-page":"1911","article-title":"Intraarterial Administration of Peptide Receptor Radionuclide Therapy in Patients with Advanced Meningioma: Initial Safety and Efficacy","volume":"65","author":"Amerein","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_28","first-page":"65","article-title":"Novel Fibroblast Activation Protein Inhibitor-Based Targeted Theranostics for Radioiodine-Refractory Differentiated Thyroid Cancer Patients: A Pilot Study","volume":"32","author":"Ballal","year":"2022","journal-title":"Thyroid"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e444","DOI":"10.1097\/RLU.0000000000004164","article-title":"First-in-Human Experience with 177Lu-DOTAGA.(SA.FAPi)2 Therapy in an Uncommon Case of Aggressive Medullary Thyroid Carcinoma Clinically Mimicking as Anaplastic Thyroid Cancer","volume":"47","author":"Ballal","year":"2022","journal-title":"Clin. Nucl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1158\/1078-0432.CCR-23-1983","article-title":"Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine-Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study","volume":"29","author":"Fu","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1097\/RLU.0000000000004260","article-title":"FAP-Targeted Radionuclide Therapy of Advanced Radioiodine-Refractory Differentiated Thyroid Cancer with Multiple Cycles of 177 Lu-FAPI-46","volume":"47","author":"Fu","year":"2022","journal-title":"Clin. Nucl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1097\/RLU.0000000000003810","article-title":"Feasibility and Therapeutic Potential of 177Lu-Fibroblast Activation Protein Inhibitor-46 for Patients with Relapsed or Refractory Cancers: A Preliminary Study","volume":"46","author":"Assadi","year":"2021","journal-title":"Clin. Nucl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1007\/s00259-021-05634-3","article-title":"FAP-targeted radionuclide therapy with [(177)Lu]Lu-FAPI-46 in metastatic nasopharyngeal carcinoma","volume":"49","author":"Fu","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1097\/RLU.0000000000004051","article-title":"Fibroblast Activation Protein Inhibitor Imaging and Therapy in a Patient with Multiple Endocrine Neoplasia Type 2A Syndrome","volume":"47","author":"Barashki","year":"2022","journal-title":"Clin. Nucl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"90S","DOI":"10.2967\/jnumed.115.170175","article-title":"Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer","volume":"57","author":"Rowe","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2214\/AJR.11.6797","article-title":"Molecular theranostics: A primer for the imaging professional","volume":"197","author":"Lee","year":"2011","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Quintos-Meneses, H.A., Aranda-Lara, L., Morales-Avila, E., Torres-Garcia, E., Camacho-Lopez, M.A., Sanchez-Holguin, M., Luna-Gutierrez, M.A., Ramirez-Duran, N., and Isaac-Olive, K. (2020). In vitro irradiation of doxorubicin with (18)F-FDG Cerenkov radiation and its potential application as a theragnostic system. J. Photochem. Photobiol. B, 210.","DOI":"10.1016\/j.jphotobiol.2020.111961"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000531246","article-title":"Efficacy and Safety of Actinium-225 Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Prostate Cancer: A Systematic Review and Metanalysis","volume":"32","author":"Parida","year":"2023","journal-title":"Med. Princ. Pract."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Wang, J.H., and Kiess, A.P. (2023). PSMA-targeted therapy for non-prostate cancers. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1220586"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [(177)Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): Secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Rizzo, A., Racca, M., Dall\u2019Armellina, S., Delgado Bolton, R.C., Albano, D., Dondi, F., Bertagna, F., Annunziata, S., and Treglia, G. (2023). Potential Role of PSMA-Targeted PET in Thyroid Malignant Disease: A Systematic Review. Diagnostics, 13.","DOI":"10.3390\/diagnostics13030564"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s12032-020-01427-0","article-title":"The prostate-specific membrane antigen (PSMA)-targeted radiotracer (18)F-DCFPyL detects tumor neovasculature in metastatic, advanced, radioiodine-refractory, differentiated thyroid cancer","volume":"37","author":"Santhanam","year":"2020","journal-title":"Med. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1007\/s12105-022-01456-3","article-title":"Immunohistochemical Expression Pattern of Theragnostic Targets SSTR2 and PSMA in Endolymphatic Sac Tumors: A Single Institution Case Series","volume":"16","author":"Brada","year":"2022","journal-title":"Head Neck Pathol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"(177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): Final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_46","first-page":"1599","article-title":"Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma","volume":"47","author":"Krenning","year":"2006","journal-title":"J. Nucl. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s00259-012-2124-x","article-title":"PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma","volume":"39","author":"Hanscheid","year":"2012","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1097\/RLU.0000000000002328","article-title":"Complementary Molecular and Metabolic Characterization of Meningiomas with DOTATATE and FDG-PET: Advancing Treatment Planning and Prognostication","volume":"44","author":"Dressen","year":"2019","journal-title":"Clin. Nucl. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1097\/RLU.0000000000002077","article-title":"Lung Metastases of Intracranial Atypical Meningioma Diagnosed on Posttherapeutic Imaging After 177Lu-DOTATATE Therapy","volume":"43","author":"Backhaus","year":"2018","journal-title":"Clin. Nucl. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein","volume":"59","author":"Lindner","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","article-title":"Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention","volume":"60","author":"Loktev","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2967\/jnumed.123.266390","article-title":"Initial Experience with (68)Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer","volume":"65","author":"Koshkin","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/s00259-022-06052-9","article-title":"Current research topics in FAPI theranostics: A bibliometric analysis","volume":"50","author":"Keijsers","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Guglielmo, P., Alongi, P., Baratto, L., Conte, M., Abenavoli, E.M., Buschiazzo, A., Celesti, G., Dondi, F., Filice, R., and Gorica, J. (2024). FAPi-Based Agents in Thyroid Cancer: A New Step towards Diagnosis and Therapy? A Systematic Review of the Literature. Cancers, 16.","DOI":"10.3390\/cancers16040839"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.21037\/tcr-23-2296","article-title":"Head-to-head comparison of [(68)Ga]Ga-FAPI-04 PET and [(18)F]FDG PET in the detection of cancer recurrence: A systematic review and meta-analysis","volume":"13","author":"Wu","year":"2024","journal-title":"Transl. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1021\/acs.jmedchem.0c02171","article-title":"Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules","volume":"64","author":"Slania","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/RLU.0000000000003667","article-title":"Safety of Fibroblast Activation Protein-Targeted Radionuclide Therapy by a Low-Dose Dosimetric Approach Using 177Lu-FAPI04","volume":"46","author":"Kuyumcu","year":"2021","journal-title":"Clin. Nucl. Med."},{"key":"ref_58","first-page":"116","article-title":"Carbonic anhydrase IX-based tumor imaging and therapy: A review","volume":"39","author":"Lin","year":"2023","journal-title":"Sheng Wu Gong Cheng Xue Bao"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.bmc.2012.09.062","article-title":"Carbonic anhydrase IX as a target for metastatic disease","volume":"21","author":"Gieling","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ijrobp.2010.11.059","article-title":"High stromal carbonic anhydrase IX expression is associated with decreased survival in P16-negative head-and-neck tumors","volume":"80","author":"Brockton","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.phro.2021.08.004","article-title":"Imaging carbonic anhydrase IX as a method for monitoring hypoxia-related radioresistance in preclinical head and neck cancer models","volume":"19","author":"Huizing","year":"2021","journal-title":"Phys. Imaging Radiat. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Huizing, F.J., Garousi, J., Lok, J., Franssen, G., Hoeben, B.A.W., Frejd, F.Y., Boerman, O.C., Bussink, J., Tolmachev, V., and Heskamp, S. (2019). CAIX-targeting radiotracers for hypoxia imaging in head and neck cancer models. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-54824-5"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1039\/D3SC06365H","article-title":"Tumor targeted alpha particle therapy with an actinium-225 labelled antibody for carbonic anhydrase IX","volume":"15","author":"Morgan","year":"2024","journal-title":"Chem. Sci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.7150\/thno.20982","article-title":"Cancer radiotheranostics targeting carbonic anhydrase-IX with (111)In- and (90)Y-labeled ureidosulfonamide scaffold for SPECT imaging and radionuclide-based therapy","volume":"8","author":"Iikuni","year":"2018","journal-title":"Theranostics"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1055\/a-2194-9965","article-title":"CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges","volume":"63","author":"Werner","year":"2024","journal-title":"Nuklearmedizin"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1053\/j.semnuclmed.2023.09.002","article-title":"Advances in PET Imaging of the CXCR4 Receptor: [(68)Ga]Ga-PentixaFor","volume":"54","author":"Lindenberg","year":"2024","journal-title":"Semin. Nucl. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"109236","DOI":"10.1016\/j.dib.2023.109236","article-title":"A dataset of [(68)Ga]Ga-Pentixafor PET\/CT images of patients with high-grade Glioma","volume":"48","author":"Roustaei","year":"2023","journal-title":"Data Brief"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1097\/RLU.0000000000005073","article-title":"68 Ga-Pentixafor PET\/CT for In Vivo Imaging of CXCR4 Receptors in Glioma Demonstrating a Potential for Response Assessment to Radiochemotherapy: Preliminary Results","volume":"49","author":"Waheed","year":"2024","journal-title":"Clin. Nucl. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3348\/kjr.2023.0091","article-title":"Research Progress of CXCR4-Targeting Radioligands for Oncologic Imaging","volume":"24","author":"Wang","year":"2023","journal-title":"Korean J. Radiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s41181-024-00282-y","article-title":"Preclinical evaluation of CXCR4 peptides for targeted radionuclide therapy in glioblastoma","volume":"9","author":"Waked","year":"2024","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","article-title":"European Association of Nuclear Medicine Practice Guideline\/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma","volume":"46","author":"Taieb","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1097\/MNM.0000000000001096","article-title":"Prospective evaluation of 68Ga-DOTANOC positron emission tomography\/computed tomography and 131I-meta-iodobenzylguanidine single-photon emission computed tomography\/computed tomography in extra-adrenal paragangliomas, including uncommon primary sites and to define their diagnostic roles in current scenario","volume":"40","author":"Arora","year":"2019","journal-title":"Nucl. Med. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/RLU.0000000000005184","article-title":"High-Specific-Activity 131 I-MIBG for the Treatment of Advanced Pheochromocytoma and Paraganglioma","volume":"49","author":"Brondani","year":"2024","journal-title":"Clin. Nucl. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2967\/jnumed.118.220665","article-title":"Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine","volume":"61","author":"Solnes","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"10904","DOI":"10.1038\/s41467-024-55291-x","article-title":"The Theranostic Genome","volume":"15","author":"Xu","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1038\/s41467-023-40826-5","article-title":"Theranostic imaging and multimodal photodynamic therapy and immunotherapy using the mTOR signaling pathway","volume":"14","author":"Zhou","year":"2023","journal-title":"Nat. Commun."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/4\/695\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:37:22Z","timestamp":1760027842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/4\/695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":78,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["cancers17040695"],"URL":"https:\/\/doi.org\/10.3390\/cancers17040695","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]}}}